R. Kornowski et al., PARADOXIC DECREASES IN ATHEROSCLEROTIC PLAQUE MASS IN INSULIN-TREATEDPATIENTS, The American journal of cardiology, 81(11), 1998, pp. 1298-1304
This study assessed the impact of diabetes mellitus on atherosclerotic
lesion formation. Seventy insulin-treated diabetics, 150 nan-insulin-
treated diabetics, and 607 nondiabetics with chronic anginal syndomes
and de nova native coronary stenoses were studied using (1) angiograph
y, and (2) intravascular ultrasound (reference and lesion arterial, lu
men, and plaque areas; area stenosis [reference-lesion/reference lumen
area]; remodeling index [reference-lesion lumen area/lesion-reference
plaque area]; and slope of the regression line relating lumen area to
plaque burden [plaque/arterial area]). Despite being diabetic for lon
ger and having similar lumen compromise, insulin-treated patients had
(1) less reference plaque (8.3 +/- 3.4 vs 10.5 +/- 4.5 mm(2) p = 0.001
5), (2) less stenosis plaque (13.0 +/- 4.9 vs 16.9 mm(2), p <0.0001),
(3) smaller reference arterial areas (17.1 +/- 5.4 vs 19.7 +/- 6.2 mm(
2), p = 0.0063), and (4) smaller stenosis arterial areas (15.3 +/- 4.9
vs 19.5 +/- 6.5 mm(2), p <0.0001) than non-insulin-treated diabetics.
With use of multivariate linear regression analysis, insulin use was
an independent land negative) predictor of reference plaque and arteri
al areas (p = 0.0308 and p = 0.0179) and stenosis plaque and arterial
areas (p = 0.0117 and p = 0.0066). This was also true when normalized
for body surface area. The remodeling index showed that insulin treatm
ent resulted in an exaggerated impact of plaque accumulation on lumen
compromise. This was confirmed by the slope of the regression line rel
ating lumen area to plaque burden. Patients with a longer duration of
diabetes who were treated with insulin for greater than or equal to 1
year had (paradoxically) less reference segment and stenosis plaque ac
cumulation. Possible explanations include impaired adaptive remodeling
and/or arterial land plaque) shrinkage. (C) 1998 by Excerpta Medica,
Inc.